The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of disease progression pattern during third-line chemotherapy with nivolumab with poor prognosis in advanced gastric cancer: A multicenter retrospective study in Japan.
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck KGaA; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Masahiko Aoki
No Relationships to Disclose
 
Takeshi Suzuki
No Relationships to Disclose
 
Naoki Takahashi
Honoraria - Ono Pharmaceutical
 
Hiromichi Shirasu
No Relationships to Disclose
 
Takayuki Ando
No Relationships to Disclose
 
Yoshiyuki Yamamoto
Honoraria - Bayer; Daiichi Sankyo; Eisai; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Kentaro Kawakami
No Relationships to Disclose
 
Yosuke Kito
Honoraria - Chugai Pharma; Merck; Taiho Pharmaceutical; Takeda
 
Toshihiko Matsumoto
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
 
Keitaro Shimozaki
No Relationships to Disclose
 
Yasuhiro Miyazaki
Research Funding - Ono Pharmaceutical
 
Toshifumi Yamaguchi
Employment - Chugai Pharma; Ono Pharmaceutical; Yakult Honsha
 
Kohei Akiyoshi
No Relationships to Disclose
 
Eishi Baba
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Daiichi Sankyo
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck; Miyarisan pharmaceutical; MSD; Sanofi; Sanofi; Taiho Pharmaceutical; Tsumura & Co.; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Akitaka Makiyama
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Lilly Japan
 
Koji Nakashima
No Relationships to Disclose
 
Naotoshi Sugimoto
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Solasia Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Kengo Nagashima
Consulting or Advisory Role - Fujimoto; Senju Pharmaceutical; Toray Industries
Speakers' Bureau - Pfizer
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)